Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Brief Comoros.
Press releases published on September 4, 2025
Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc.
GlobeNewswire
·
September 4, 2025
PUNE, India, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Biorad Medisys, an Indian medical device manufacturer with a global footprint, has announced its entry into the US market with the launch of its subsidiary Medtimo Inc. The move comes post Biorad Medisys’ …
MD Logic Health and Dr. Roxanne Carfora Launch Advanced Cholesterol Support: A Doctor-Created Formula for Heart and Metabolic Wellness
GlobeNewswire
·
September 4, 2025
Miami, Florida , Sept. 04, 2025 (GLOBE NEWSWIRE) -- MD Logic Health®, a trusted leader in science-backed wellness solutions, has partnered with Dr. Roxanne Carfora, D.O., P.C., a Board Certified Anti-Aging and Regenerative Medicine Specialist, to launch …
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
GlobeNewswire
·
September 4, 2025
Results from long-term follow up of patients treated with atrioventricular interval modulation (“AVIM”) therapy show blood pressure-lowering effects are sustained for years after activation, reversible with no observed rebound hypertension upon …
ADARx Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire
·
September 4, 2025
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on …
Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
September 4, 2025
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye …
Catheter Precision Announces September 10th, 2025 Record Date for October 10th, 2025 Special Meeting of Stockholders
GlobeNewswire
·
September 4, 2025
FORT MILL, S.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that September …
NBME celebrates 110th anniversary of advancing assessment in medical education
GlobeNewswire
·
September 4, 2025
PHILADELPHIA, Sept. 04, 2025 (GLOBE NEWSWIRE) -- This year, NBME celebrates 110 years of creating high-quality assessments for medical learners. As a not-for-profit organization, NBME aims to advance assessment of health care professionals to achieve …
Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference
GlobeNewswire
·
September 4, 2025
CHASKA, Minn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 24th Annual …
TISSIUM Advances Clinical Pipeline in Hernia Repair Following First FDA Authorization
GlobeNewswire
·
September 4, 2025
Paris, France, Cambridge, USA, September 4 2025 - TISSIUM, a MedTech company pioneering biomorphic programmable polymers for tissue reconstruction, today announced further progress in its clinical pipeline of atraumatic solutions following the recent U.S. …
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
September 4, 2025
CONSHOHOCKEN, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it …
Regeneron Announces Updated Presentation Time for Upcoming Investor Conference
GlobeNewswire
·
September 4, 2025
TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Monday, September 8, 2025. The …
STRATA Skin Sciences Announces Closing of $2.42 Million Registered Direct Offering
GlobeNewswire
·
September 4, 2025
HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of …
Service Coordination, Inc. President & CEO John Dumas Named One of Maryland’s 2025 Most Admired CEOs
GlobeNewswire
·
September 4, 2025
Frederick, MD, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The Daily Record has named John Dumas, President …
Silent Killer: HTLV 2026 Conference Launches Global Campaign to Fight HIV’s “Cousin” Virus Infecting Millions
GlobeNewswire
·
September 4, 2025
Philadelphia, PA , Sept. 04, 2025 (GLOBE NEWSWIRE) -- HTLV 2026, the international conference dedicated to advance discovery research on Human T-cell Leukemia Virus Type 1 (HTLV-1), today announced the launch of a global awareness campaign to combat the …
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
GlobeNewswire
·
September 4, 2025
Another addition to Amneal’s growing complex injectables portfolio reflects leadership in advanced development and manufacturing of complex pharmaceuticals BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the …
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire
·
September 4, 2025
RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), …
Praxis Precision Medicines to Participate in September Investor Conferences
GlobeNewswire
·
September 4, 2025
BOSTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders …
Indaptus Therapeutics Provides Clinical Update
GlobeNewswire
·
September 4, 2025
Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- …
Inventiva to Participate in Upcoming September Investor Conferences
GlobeNewswire
·
September 4, 2025
Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment …
Inventiva annonce sa participation à plusieurs conférences investisseurs en septembre
GlobeNewswire
·
September 4, 2025
Daix (France), New York City (New York, Etats-Unis), le 4 septembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de …